Experimental COVID-19 Vaccines Approach the Finish-Line

The COVID-19 vaccine development landscape includes innovative platforms such as nucleic acid (DNA and RNA), virus-like particle, peptide, viral vector, recombinant protein, live attenuated virus, and inactivated virus approaches.

The goal of these vaccine candidates is to prevent SARS-CoV-2, the coronavirus that causes COVID-19, from getting into cells, replicating itself, which then infects a person, says the U.S. FDA.

As of November 30, 2020, the FDA has not authorized any of these experimental coronavirus vaccine candidates.